Pharmacokinetics and tolerance of intravenous and intramuscular phylloquinone (vitamin K1) mixed micelles formulation. 1996

J R Soedirman, and E A De Bruijn, and R A Maes, and A Hanck, and J Grüter
F. Hoffmann-La Roche & Co. Ltd Basel, Switzerland.

1. The pharmacokinetics and tolerance of phylloquinone(vitamin K1) mixed micelles formulation (Konakion MM) were evaluated, in normal human adult volunteers (n = 30) using an open randomized crossover design protocol following a 10 mg intravenous or intramuscular injection. 2. Blood samples were collected for up to 12 h after the intravenous and up to 72 h after the intramuscular injections and the phylloquinone(vitamin K1) levels determined by reversed phase h.p.l.c. with fluorometric detection after post-column electrochemical reduction. 3. Konakion MM was well tolerated after either route of administration. Pharmacokinetic analysis of plasma phylloquinone(vitamin K1) concentration vs time profiles revealed that in one-fifth of the subjects systemic availability of intramuscular phylloquinone (vitamin K1) was below 65%. 4. Our data suggest that due to sustained, but irregular and unpredictable absorption of the phylloquinone(vitamin K1) from the depot site, the intramuscular route of Konakion MM administration is not suitable and thus not recommended. 5. Konakion MM i.v. is indicated to be well tolerated and effective in antagonizing coumarin-type-anticoagulants like Marcoumar.

UI MeSH Term Description Entries
D007273 Injections, Intramuscular Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it. Intramuscular Injections,Injection, Intramuscular,Intramuscular Injection
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008297 Male Males
D008823 Micelles Particles consisting of aggregates of molecules held loosely together by secondary bonds. The surface of micelles are usually comprised of amphiphatic compounds that are oriented in a way that minimizes the energy of interaction between the micelle and its environment. Liquids that contain large numbers of suspended micelles are referred to as EMULSIONS. Micelle
D010837 Vitamin K 1 A family of phylloquinones that contains a ring of 2-methyl-1,4-naphthoquinone and an isoprenoid side chain. Members of this group of vitamin K 1 have only one double bond on the proximal isoprene unit. Rich sources of vitamin K 1 include green plants, algae, and photosynthetic bacteria. Vitamin K1 has antihemorrhagic and prothrombogenic activity. Phylloquinone,Phytomenadione,Phytonadione,Aquamephyton,Konakion,Phyllohydroquinone,Vitamin K1
D004339 Drug Compounding The preparation, mixing, and assembly of a drug. (From Remington, The Science and Practice of Pharmacy, 19th ed, p1814). Drug Formulation,Drug Preparation,Drug Microencapsulation,Pharmaceutical Formulation,Compounding, Drug,Formulation, Drug,Formulation, Pharmaceutical,Microencapsulation, Drug,Preparation, Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities

Related Publications

J R Soedirman, and E A De Bruijn, and R A Maes, and A Hanck, and J Grüter
March 2013, European journal of clinical pharmacology,
J R Soedirman, and E A De Bruijn, and R A Maes, and A Hanck, and J Grüter
March 2005, Journal of hepatology,
J R Soedirman, and E A De Bruijn, and R A Maes, and A Hanck, and J Grüter
January 2017, Mini reviews in medicinal chemistry,
J R Soedirman, and E A De Bruijn, and R A Maes, and A Hanck, and J Grüter
February 1977, Proceedings of the Royal Society of Medicine,
J R Soedirman, and E A De Bruijn, and R A Maes, and A Hanck, and J Grüter
January 1970, Acta chemica Scandinavica,
J R Soedirman, and E A De Bruijn, and R A Maes, and A Hanck, and J Grüter
November 1995, Thrombosis and haemostasis,
J R Soedirman, and E A De Bruijn, and R A Maes, and A Hanck, and J Grüter
May 1993, Journal of pediatric gastroenterology and nutrition,
J R Soedirman, and E A De Bruijn, and R A Maes, and A Hanck, and J Grüter
February 1988, The Journal of pharmacy and pharmacology,
J R Soedirman, and E A De Bruijn, and R A Maes, and A Hanck, and J Grüter
January 2012, International journal of nanomedicine,
J R Soedirman, and E A De Bruijn, and R A Maes, and A Hanck, and J Grüter
February 1994, Acta paediatrica (Oslo, Norway : 1992),
Copied contents to your clipboard!